Form 4: Mineralys Therapeutics CFO Adam Levy Reports Stock Option Grant

Adam Levy, CFO and Secretary of Mineralys Therapeutics, reports the acquisition of stock options.

Summary

• Adam Levy, the CFO and Secretary of Mineralys Therapeutics, filed a Form 4 with the SEC.
• The filing reports the grant of stock options for 170,000 shares of Mineralys Therapeutics common stock on February 13, 2025.
• The exercise price of the stock options is $10.20.
• The options vest in monthly installments over four years, starting from the grant date, with 1/48th of the total shares vesting each month.
• The expiration date for the options is February 13, 2035.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Comparable companies such as BioNTech, Moderna, and Novavax also utilize stock options as part of their executive compensation plans.
• The vesting schedule of four years is typical for stock option grants.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the company performs well and the options become valuable.

Key Dates

Keywords

Form 4, Stock Options, Mineralys Therapeutics, MLYS, Adam Levy, CFO, Beneficial Ownership, SEC Filing